Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney M P Hollowell

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Urology|July 27, 2021
EDITORIAL COMMENTCourtney M P Hollowell
The Journal of Urology|March 11, 2021
Editorial CommentCourtney M P Hollowell
The New England Journal of Medicine|April 23, 2010
Images in clinical medicine. Calcifications in a continent urinary diversionMarc A Bjurlin, Courtney M P Hollowell
Medical Oncology (Northwood, London, England)|April 28, 2010
Bax expression remains unchanged following antisense treatment directed against BCL-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2013
Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|November 8, 2015
Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor ProliferationMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|July 15, 2011
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expressionMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|August 27, 2011
In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotidesMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2011
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFRMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|December 14, 2011
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Urology|July 27, 2021
EDITORIAL COMMENTCourtney M P Hollowell
The Journal of Urology|March 11, 2021
Editorial CommentCourtney M P Hollowell
The New England Journal of Medicine|April 23, 2010
Images in clinical medicine. Calcifications in a continent urinary diversionMarc A Bjurlin, Courtney M P Hollowell
Medical Oncology (Northwood, London, England)|April 28, 2010
Bax expression remains unchanged following antisense treatment directed against BCL-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2013
Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|November 8, 2015
Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor ProliferationMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
In Vivo (Athens, Greece)|July 15, 2011
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expressionMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|August 27, 2011
In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotidesMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2011
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFRMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|December 14, 2011
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Pageof 8